

Lars Wallentin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7361887/lars-wallentin-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234
papers

33,624
citations

62
h-index

182
g-index

264
ext. papers

39,962
ext. citations

9.7
avg, IF

6.48
L-index

#	Paper	IF	Citations
234	Dabigatran versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 361, 1139-51	59.2	7909
233	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
232	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
231	Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. <i>New England Journal of Medicine</i> , 2007 , 356, 1009-19	59.2	962
230	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 354, 1464-76	59.2	922
229	The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 321-8	15.1	585
228	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017 , 389, 1025-1034	40	543
227	The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART). <i>Heart</i> , 2010 , 96, 1617-21	5.1	414
226	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
225	Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. <i>European Heart Journal</i> , 2008 , 29, 21-30	9.5	356
224	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , 2010 , 159, 331-9	4.9	345
223	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology, The</i> , 2010 , 9, 1157-1163	24.1	329
222	Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2009 , 157, 599-605	4.9	302
221	Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. <i>Circulation</i> , 2012 , 125, 1605-16	16.7	291
220	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	40	272
219	Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1677-84	27.4	271
218	Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017 , 63, 140-151	5.5	256

217	Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>American Heart Journal</i> , 2009 , 157, 805-10, 810.e1-2	4.9	256
216	Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. <i>Circulation</i> , 2014 , 129, 1568-76	16.7	250
215	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237
214	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1582-90	9.5	235
213	A catalog of genetic loci associated with kidney function from analyses of a million individuals. <i>Nature Genetics</i> , 2019 , 51, 957-972	36.3	217
212	Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. <i>Lancet, The</i> , 2014 , 383, 1305-1312	4.0	202
211	5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. <i>Lancet, The</i> , 2006 , 368, 998-1004	4.0	201
210	Biomarkers in atrial fibrillation: a clinical review. <i>European Heart Journal</i> , 2013 , 34, 1475-80	9.5	195
209	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 130, 1847-58	16.7	188
208	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. <i>Nature Genetics</i> , 2018 , 50, 26-41	36.3	186
207	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDHEART registry 1995-2014. <i>European Heart Journal</i> , 2017 , 38, 3056-3065	9.5	174
206	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017 , 377, 1132-1142	59.2	170
205	Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial	15.1	164
204	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016 , 388, 1161-9	4.0	157
203	N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 2274-84	15.1	149
202	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014 , 35, 2083-93	9.5	141
201	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2481-93	15.1	130
200	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129

199	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017 , 38, 804-810	9.5	114
198	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	15.1	114
197	The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. <i>European Heart Journal</i> , 2005 , 26, 308-13	9.5	113
196	Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. <i>European Heart Journal</i> , 2016 , 37, 3335-3342	9.5	109
195	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
194	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1689-1700	15.1	101
193	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 451-60	16.2	100
192	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015 , 36, 1264-72	9.5	99
191	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	15.1	99
190	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadib Therapy) comparing darapladib versus placebo in patients with coronary heart disease. <i>American Heart Journal</i> , 2010 , 160, 655-61	4.9	97
189	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. <i>European Heart Journal</i> , 2016 , 37, 1325-33	9.5	91
188	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016 , 353, i2868	5.9	86
187	GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. <i>PLoS ONE</i> , 2013 , 8, e78797	3.7	85
186	Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2014 , 129, 2003-2012	16.7	79
185	Comparison of hospital variation in acute myocardial infarction care and outcome between Sweden and United Kingdom: population based cohort study using nationwide clinical registries. <i>BMJ, The</i> , 2015 , 351, h3913	5.9	77
184	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016 , 37, 1993-2001	9.5	77
183	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. <i>European Heart Journal</i> , 2015 , 36, 1901-12	9.5	75
182	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015 , 170, 1151-60	4.9	73

181	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018 , 39, 1078-1085	9.5	73
180	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 534-543	18.1	69
179	Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1541-50	15.1	67
178	Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 734-42	3.9	65
177	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015 , 169, 899-905.e1	4.9	65
176	ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing. <i>PLoS ONE</i> , 2011 , 6, e25583	3.7	65
175	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018 , 39, 3766-3776	9.5	65
174	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , 2018 , 39, 477-485	9.5	63
173	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017 , 63, 325-333	5.5	62
172	Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals. <i>American Journal of Human Genetics</i> , 2016 , 99, 40-55	11	61
171	ST2 and mortality in non-ST-segment elevation acute coronary syndrome. <i>American Heart Journal</i> , 2010 , 159, 788-94	4.9	61
170	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018 , 39, 1672-1686f	9.5	59
169	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1015-1023	5.1	58
168	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016 , 134, 1697-1707	16.7	58
167	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 813-826	15.1	58
166	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2014 , 35, 1541-50	9.5	53
165	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 4037-4046	9.5	52
164	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. <i>Clinical Chemistry</i> , 2017 , 63, 152-164	5.5	51

163	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016 , 102, 508-17	5.1	51
162	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2016 , 388, 1903-1911	4.0	49
161	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016 , 102, 617-25	5.1	48
160	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 678-85	3.9	47
159	Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. <i>American Journal of Human Genetics</i> , 2016 , 99, 8-21	11	47
158	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46
157	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2135-2144	15.1	46
156	Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. <i>Circulation</i> , 2020 , 142, 150-160	16.7	44
155	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
154	Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution. <i>Nature Genetics</i> , 2019 , 51, 452-469	36.3	44
153	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019 , 42, 568-573	7.1	43
152	Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial. <i>American Heart Journal</i> , 2004 , 148, 566-73	4.9	43
151	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016 , 102, 926-33	5.1	43
150	Large-Scale Exome-wide Association Analysis Identifies Loci for White Blood Cell Traits and Pleiotropy with Immune-Mediated Diseases. <i>American Journal of Human Genetics</i> , 2016 , 99, 22-39	11	42
149	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014 , 100, 1193-200	5.1	39
148	Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1493-9	15.1	39
147	Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1048-57	15.1	38
146	Therapeutic hypothermia for the treatment of acute myocardial infarction-combined analysis of the RAPID MI-ICE and the CHILL-MI trials. <i>Therapeutic Hypothermia and Temperature Management</i> , 2015 , 5, 77-84	1.3	38

145	New Generation Cardiac Troponin I Assay for the Access Immunoassay System. <i>Clinical Chemistry</i> , 2001 , 47, 959-961	5.5	37
144	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1549-1559	15.1	36
143	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020 , 141, 1384-1392	16.7	36
142	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	36
141	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 255-267	15.1	36
140	Temporal trends in bleeding events in acute myocardial infarction: insights from the SWEDEHEART registry. <i>European Heart Journal</i> , 2020 , 41, 833-843	9.5	36
139	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 771-8	3.9	35
138	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019 , 208, 123-131	4.9	35
137	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017 , 190, 94-103	4.9	34
136	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 2242-8a	9.5	34
135	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014 , 100, 1762-9	5.1	34
134	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. <i>JAMA Cardiology</i> , 2018 , 3, 1160-1166	16.2	34
133	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017 , 38, 1048-1055	9.5	33
132	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. <i>American Heart Journal</i> , 2015 , 169, 879-889.e7	4.9	33
131	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017 , 38, 2813-2822	9.5	33
130	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018 , 283, 83-92	10.8	31
129	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e002490	6	30
128	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016 , 102, 57-62	5.1	30

127	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
126	Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 5-12	6.4	30
125	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016 , 202, 589-94	3.2	29
124	Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?. <i>American Heart Journal</i> , 2014 , 168, 611-21	4.9	29
123	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	5.5	29
122	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 839-46	3.9	28
121	Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). <i>American Heart Journal</i> , 2016 , 175, 36-46	4.9	28
120	D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 921-30	7	28
119	Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 671-83	5	26
118	EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials. <i>European Heart Journal</i> , 2019 , 40, 2745-2749	9.5	25
117	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
116	Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 707-16	27.4	24
115	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016 , 139, 77-81	8.2	23
114	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1666-1676	16.7	23
113	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 721-733	15.1	21
112	Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 465-76	15.1	21
111	Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 573-584	5.5	20
110	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20

109	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1145-1155	15.1	19
108	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2016 , 177, 1-8	4.9	18
107	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016 , 17, 1425-39	2.6	18
106	From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1618-1636	15.1	17
105	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
104	Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. <i>American Heart Journal</i> , 2014 , 168, 869-77.e1	4.9	17
103	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	16
102	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. <i>Journal of Internal Medicine</i> , 2018 , 283, 282-292	10.8	16
101	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016 , 18, 973-8	3.9	16
100	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
99	Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 665-73	3	16
98	Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 936-44	3	16
97	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
96	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATElet inhibition and patient Outcomes study. <i>American Heart Journal</i> , 2014 , 168, 96-102.e2	4.9	15
95	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017 , 245, 271-276	3.2	15
94	European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 ,	4.6	15
93	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021 , 18, e1003513	11.6	14
92	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 500-510	4.3	13

91	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017 , 48, 3266-3273	6.7	13
90	Understanding the use of observational and randomized data in cardiovascular medicine. <i>European Heart Journal</i> , 2020 , 41, 2571-2578	9.5	13
89	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1424-1437	12.3	13
88	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. <i>Clinical Chemistry</i> , 2016 , 62, 485-93	5.5	13
87	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
86	Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002314	6	13
85	Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014 , 113, 669-75	3	13
84	Relative efficacy and safety of ticagrelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. <i>Clinical Cardiology</i> , 2017 , 40, 390-398	3.3	12
83	Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. <i>Journal of the American Heart Association</i> , 2015 , 4, e001512	6	12
82	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014 , 168, 68-75.e2	4.9	12
81	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. <i>American Heart Journal</i> , 2014 , 168, 622-31	4.9	12
80	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 246-56	4.3	12
79	Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. <i>Heart</i> , 2015 , 101, 119-25	5.1	12
78	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 412-422	7	12
77	Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019 , 39, 294-302	9.4	12
76	Platelet-related biomarkers and their response to inhibition with aspirin and p2y-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 145-153	5.1	11
75	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020 , 41, 2848-2859	9.5	11
74	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020 , 141, 10-20	16.7	11

73	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019 , 105, 235-242	5.1	11
72	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	10
71	Interleukin-18 in patients with acute coronary syndromes. <i>Clinical Cardiology</i> , 2019 , 42, 1202-1209	3.3	10
70	Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. <i>PLoS ONE</i> , 2017 , 12, e0182115	3.7	10
69	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 36-45	6.4	10
68	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
67	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016 , 140, 81-88	8.2	10
66	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020 , 22, 870-877	3.9	9
65	Extracellular vesicles in atrial fibrillation and stroke. <i>Thrombosis Research</i> , 2020 , 193, 180-189	8.2	9
64	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016 , 178, 1-8	4.9	9
63	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015 , 4,	3.2	8
62	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	6	8
61	Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 2048872619878075	16.7	8
60	Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. <i>Journal of the American Heart Association</i> , 2014 , 3,	4.2	8
59	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019 , 208, 65-73	6	7
58	Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 563-569	4.9	7
57	Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2019 , 213, 57-65	5.1	6
56		4.9	6

55	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	6
54	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. <i>American Heart Journal</i> , 2018 , 198, 169-177	4.9	6
53	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018 , 201, 25-32	4.9	6
52	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. <i>American Heart Journal</i> , 2015 , 169, 531-8	4.9	6
51	Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline. <i>Kidney International</i> , 2021 , 99, 926-939	9.9	6
50	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2287-2295	15.4	5
49	Lecithin: Cholesterol Acyl Transfer Rate in Plasma and its Relations to Lipoprotein Concentrations and to Kinetics of Bile Acids and Triglycerides in Hyperlipoproteinemic Subjects. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1978 , 38, 103-110	2	5
48	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
47	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016 , 178, 176-84	4.9	5
46	Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 492-501	4.3	5
45	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2726-2737	15.4	5
44	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017 , 119, 1135-1140	3	4
43	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 75-81	6.4	4
42	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 72, 37-43	2.1	4
41	Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATElet inhibition and patient Outcomes (PLATO) study. <i>Platelets</i> , 2019 , 30, 579-588	3.6	4
40	No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. <i>International Journal of Cardiology</i> , 2014 , 176, 300-2	3.2	4
39	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
38	Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?. <i>Frontiers in Immunology</i> , 2017 , 8, 1595	8.4	4

37	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021 , 233, 92-101	4.9	4
36	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021 , 290, 392-403	10.8	4
35	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. <i>Platelets</i> , 2021 , 1-7	3.6	4
34	Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G372-G386	5.1	4
33	The ABC risk score for patients with atrial fibrillation - AuthorsReply. <i>Lancet, The</i> , 2016 , 388, 1980-1981	4.0	3
32	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. <i>American Heart Journal</i> , 2018 , 202, 54-60	4.9	3
31	Time-based measures of treatment effect: reassessment of ticagrelor and clopidogrel from the PLATO trial. <i>Open Heart</i> , 2017 , 4, e000557	3	3
30	The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 , 7, 431-437	4.6	3
29	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021 , 149, 27-35	3	3
28	Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 549-559	3.9	3
27	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
26	Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	3
25	Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. <i>Journal of Internal Medicine</i> , 2020 , 288, 248-259	10.8	2
24	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
23	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. <i>Atherosclerosis</i> , 2020 , 293, 35-41	3.1	2
22	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
21	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. <i>American Heart Journal</i> ,	4.9	2
20	Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. <i>PLoS ONE</i> , 2018 , 13, e0204352	3.7	2

19	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 155-163	4.3	1
18	Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 427-429	7	1
17	Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 502-504	15.4	1
16	Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". <i>Circulation</i> , 2014 , 130, e195	16.7	1
15	Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". <i>Circulation</i> , 2014 , 129, e21-2	16.7	1
14	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1311-1319	3.9	1
13	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021 , 8,	3	1
12	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels <i>American Heart Journal</i> , 2020 , 225, 97-107	4.9	1
11	Cardiovascular Medicine in Sweden: Improvement by Continuous Measuring. <i>Circulation</i> , 2020 , 141, 1124-1126	4.1	1
10	P4797 Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2018 , 39,	9.5	1
9	Diabetes status modifies the long-term effect of lipoprotein-associated phospholipase A2 on major coronary events. <i>Diabetologia</i> , 2022 , 65, 101-112	10.3	1
8	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020 , 125, 1280-1283	3	0
7	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020 , 15, e0226259	3.7	0
6	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.. <i>American Heart Journal</i> , 2022 , 251, 13-13	4.9	0
5	Unreliable Observations from a Confounded Analysis of a Skewed Database. <i>American Journal of Medicine</i> , 2017 , 130, e355-e356	2.4	
4	Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". <i>Circulation</i> , 2014 , 130, e95	16.7	
3	Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. <i>European Heart Journal</i> , 2013 , 34, 4536-4536	9.5	
2	Reduction in recurrent ischemic events with vorapaxar: results from TRACER. <i>European Heart Journal</i> , 2013 , 34, P4842-P4842	9.5	

- 1 Natriuretic peptides and incident atrial fibrillation. *American Heart Journal*, **2021**, 241, 120 4.9